Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline Pharmaceuticals Ltd.

http://www.gsk-india.com

Latest From GlaxoSmithKline Pharmaceuticals Ltd.

FTC’s Salvos Against Biopharma To Reverberate Through 2024

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

M & A Patents

VBP Pains Swell Prompting New China Strategy, Local Innovation Focus

As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.

China Commercial

What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?

The Federal Trade Commission blocked or restricted several deals last year, broadening what it considers to be anticompetitive transactions. Stakeholders are looking to see if the agency will bring similar cases this year and what remedies it will seek to allow deals to go forward.

Deals M & A

Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar

Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.

China Vaccines
See All

Company Information

UsernamePublicRestriction

Register